Cartesian Therapeutics, Inc. (RNAC) Financial Statements (2026 and earlier)

Company Profile

Business Address 7495 NEW HORIZON WAY
FREDERICK, MD 21703
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments212,61076,911134,602128,055138,68589,893
Cash and cash equivalent212,61076,911106,438114,057138,68589,893
Short-term investments   28,16413,998  
Restricted cash and investments   289  279
Receivables8725,8706,5969,9147,2245,000
Contract with customer, asset, after allowance for credit loss  2,9813,162   
Other undisclosed current assets3,1444,9673,4896,4745,4341,495
Total current assets:216,62690,729148,138144,443151,34396,667
Noncurrent Assets
Operating lease, right-of-use asset5,53510,06811,6179,82910,948301
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization9,9122,1132,7942,1421,3951,222
Intangible asset, including goodwill, after accumulated amortization198,763198,763    
Goodwill48,16348,163    
Intangible asset, excluding goodwill, after accumulated amortization150,600150,600    
Restricted cash and investments1,6691,3771,3111,3791,3791,379
Other noncurrent assets 518     
Other undisclosed noncurrent assets2,0002,0002,0262,090370 
Total noncurrent assets:218,397214,32117,74815,44014,0922,902
TOTAL ASSETS:435,023305,050165,886159,883165,43599,569
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,36417,88314,40011,3588,58913,992
Taxes payable601  
Accounts payable2883,150316224443500
Accrued liabilities12,07614,73314,08410,5338,14613,492
Deferred revenue  2,31159353,88372,0501,674
Debt   8,4765,961 19,277
Derivative instruments and hedges, liabilities  28,307    
Other undisclosed current liabilities10,61219,7081,6081,049908 
Total current liabilities:22,97668,20925,07772,25181,54734,943
Noncurrent Liabilities
Long-term debt and lease obligation   17,78628,27134,440 
Long-term debt, excluding current maturities   17,78619,67324,793 
Liabilities, other than long-term debt27,27428,18010,05511,41738,74614,680
Deferred revenue  3,538 11,41738,74614,680
Deferred income tax liabilities16,14115,853    
Operating lease, liability11,1338,78910,0558,5989,647 
Other undisclosed noncurrent liabilities391,575348,29119,14025,42328,70841,549
Total noncurrent liabilities:418,849376,47146,98165,111101,89456,229
Total liabilities:441,825444,68072,058137,362183,44191,172
Temporary equity, including noncontrolling interest  296,851    
Equity
Equity, attributable to parent(6,802)(440,184)93,82822,521(18,006)8,397
Common stock3161512119
Additional paid in capital689,887179,047493,308457,391391,175348,664
Accumulated other comprehensive loss(4,621)(4,600)(4,558)(4,566)(4,563)(4,523)
Accumulated deficit(692,071)(614,647)(394,937)(430,316)(404,629)(335,753)
Other undisclosed equity  3,703    
Total equity:(6,802)(436,481)93,82822,521(18,006)8,397
TOTAL LIABILITIES AND EQUITY:435,023305,050165,886159,883165,43599,569

Income Statement (P&L) ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues38,91326,004110,77785,07716,5976,677
Gross profit:38,91326,004110,77785,07716,5976,677
Operating expenses(82,810)(112,420)(96,239)(89,674)(73,418)(59,132)
Operating income (loss):(43,897)(86,416)14,538(4,597)(56,821)(52,455)
Nonoperating income (expense)1,102(143,907)2,38159405(519)
Investment income, nonoperating496(144,636)2,07344260834
Other nonoperating income (expense)6066913301589(1,306)
Interest and debt expense  (2,833)(3,031)(2,844)(2,017)(1,519)
Income (loss) from continuing operations before equity method investments, income taxes:(42,795)(233,156)13,888(7,382)(58,433)(54,493)
Other undisclosed income (loss) from continuing operations before income taxes (34,342)(5,554)20,882(2,339)  
Income (loss) from continuing operations before income taxes:(77,137)(238,710)34,770(9,721)(58,433)(54,493)
Income tax expense (benefit)(287)19,000609(15,966)  
Income (loss) from continuing operations:(77,424)(219,710)35,379(25,687)(58,433)(54,493)
Loss before gain (loss) on sale of properties:(25,687)(58,433)(54,493)
Net income (loss):(77,424)(219,710)35,379(25,687)(58,433)(54,493)
Other undisclosed net loss attributable to parent     (10,443)(857)
Net income (loss) attributable to parent:(77,424)(219,710)35,379(25,687)(68,876)(55,350)
Other undisclosed net loss available to common stockholders, basic  (37,550)    
Net income (loss) available to common stockholders, basic:(77,424)(257,260)35,379(25,687)(68,876)(55,350)
Dilutive securities, effect on basic earnings per share (446)     
Net income (loss) available to common stockholders, diluted:(77,870)(257,260)35,379(25,687)(68,876)(55,350)

Comprehensive Income ($ in thousands)

12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(77,424)(219,710)35,379(25,687)(58,433)(54,493)
Comprehensive income (loss):(77,424)(219,710)35,379(25,687)(58,433)(54,493)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(21)(42)8(3)(10,483)(823)
Comprehensive income (loss), net of tax, attributable to parent:(77,445)(219,752)35,387(25,690)(68,916)(55,316)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: